Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies

dc.contributor.authorCanaslan, Sezgi
dc.contributor.authorSchmitz, Matthias
dc.contributor.authorVillar Piqué, Anna
dc.contributor.authorMaass, Fabian
dc.contributor.authorGmitterová, Karin
dc.contributor.authorVarges, Daniela
dc.contributor.authorLingor, Paul
dc.contributor.authorLlorens Torres, Franc
dc.contributor.authorHermann, Peter
dc.contributor.authorZerr, Inga
dc.date.accessioned2021-10-18T07:25:10Z
dc.date.available2021-10-18T07:25:10Z
dc.date.issued2021-09-22
dc.date.updated2021-10-14T08:46:33Z
dc.description.abstractAlpha-synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are a class of neurodegenerative diseases. A diagnosis may be challenging because clinical symptoms partially overlap, and there is currently no reliable diagnostic test available. Therefore, we aimed to identify a suitable marker protein in cerebrospinal fluid (CSF) to distinguish either between different types of alpha-synucleinopathies or between alpha-synucleinopathies and controls. In this study, the regulation of different marker protein candidates, such as alpha-synuclein (a-Syn), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and total tau (tau) in different types of alpha-synucleinopathies, had been analyzed by using an ultrasensitive test system called single-molecule array (SIMOA). Interestingly, we observed that CSF-NfL was significantly elevated in patients with DLB and MSA compared to patients with PD or control donors. To differentiate between groups, receiver operating characteristic (ROC) curve analysis resulted in a very good diagnostic accuracy as indicated by the area under the curve (AUC) values of 0.87-0.92 for CSF-NfL. Furthermore, we observed that GFAP and tau were slightly increased either in DLB or MSA, while a-Syn levels remained unregulated. Our study suggests NfL as a promising marker to discriminate between different types of alpha-synucleinopathies or between DLB/MSA and controls.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid34630068
dc.identifier.urihttps://hdl.handle.net/2445/180635
dc.language.isoeng
dc.publisherFrontiers Media SA
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fnagi.2021.717930
dc.relation.ispartofFrontiers in Aging Neuroscience, 2021, vol. 13 num. 717930
dc.relation.urihttps://doi.org/10.3389/fnagi.2021.717930
dc.rightscc by (c) Canaslan, Sezgi et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationLíquid cefalorraquidi
dc.subject.classificationMalalties neurodegeneratives
dc.subject.otherCerebrospinal fluid
dc.subject.otherNeurodegenerative Diseases
dc.titleDetection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
fnagi-13-717930.pdf
Mida:
2.09 MB
Format:
Adobe Portable Document Format